Technosphere Insulin News Today : Breaking News, Live Updates & Top Stories | Vimarsana

MannKind Presents Poster at 15th International Conference on Advanced Technologies & Treatments for Diabetes (ATTD 2022) to Be Held April 27-30

27.04.2022 - Simplified 2x dose of Technosphere Insulin (TI) produced a statistically significant improvement in PPGE between Dose 1 & 2 from 45-120 minutesHigher dose of TI resulted in a mean difference of 52 mg/dL in PPGE at 120 minutes, with no new safety . Seite 1

Comunidad autonoma de catalunaKevin kaisermanTimothys baileyMannkind corporation nasdaqAffairs safetyKind corporationInternational conferenceTechnosphere insulinMedical affairsEndocrine business unit

MannKind Announces First Patient Enrolled In Inhale-1 Study Of Afrezza® In Pediatric Population

/PRNewswire/ MannKind Corporation (Nasdaq: MNKD), a company focused on the development and commercialization of inhaled therapeutic products for patients.

United statesKevin kaisermanMichaelj hallerMannkind corporation nasdaqUniversity of floridaDiabetes endocrinology centerExchange commissionMannkind corporationSafety of mannkind corporationPrnewswire mannkind corporation nasdaqKind corporationTechnosphere insulinVice presidentMedical affairsEndocrinology centerPediatric endocrinology

MannKind Announces First Patient Enrolled in INHALE-1 Study of Afrezza® in Pediatric Population

MannKind Announces First Patient Enrolled in INHALE-1 Study of Afrezza® in Pediatric Population
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

United statesRose alinayaChristie iacangeloKevin kaisermanMichaelj hallerMannkind corporation nasdaqUniversity of floridaDiabetes endocrinology centerExchange commissionMannkind corporationMannkind corporationmannkind corporation nasdaqCorporate communicationsSafety of mannkind corporationWall streetKind corporationTechnosphere insulin

MannKind Announces Data Presentation At 14th International Conference On Advanced Technologies & Treatments For Diabetes (ATTD 2021) To Be Held Virtually June 2-5

/PRNewswire/ MannKind Corporation (Nasdaq: MNKD), which focuses on the development of innovative medicines for patients with endocrine and orphan lung.

United statesKevin kaisermanExchange commissionMannkind corporationMannkind corporation nasdaqPrnewswire mannkind corporation nasdaqKind corporationInternational conferenceAdvanced technologiesTechnosphere insulinVice presidentMedical affairsAbout mannkind corporationInhalation powderWestlake villageAnnual report